Frequency Therapeutics expects FX-322-208 trial results in H2 Q1 2023

Korro Bio, Inc.

Posted updated corporate slide presentation on Dec 13, 2022.
FX-322-208 Phase 2 trial results expected second half of Q1 2023.
FX-322 is an investigational regenerative therapy for sensorineural hearing loss.

item 7.01 item 9.01

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-303234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.